A study of patients with diabetes in Hong Kong found that continued use of metformin below an estimated glomerular filtration rate (eGFR) of 30ml/min/1.73m2 was associated with a lower risk of cardiovascular and renal events, compared to those who discontinued the medication. The study followed 36,940 patients and found that discontinuing metformin was associated with a higher risk of major adverse cardiovascular events, heart failure, end-stage kidney disease, and mortality. The benefits of continued use should be weighed against the risk of lactic acidosis.
